Skip to main content

Concurrent Use of Opioids and Benzodiazepines (COB)

CBE ID
3389
Endorsement Status
1.1 New or Maintenance
Previous Endorsement Cycle
Is Under Review
No
Next Maintenance Cycle
Spring 2025
1.3 Measure Description

The percentage of individuals >=18 years of age with concurrent use of prescription opioids and benzodiazepines during the measurement year.

A lower rate indicates better performance.

        • 1.5 Measure Type
          1.7 Electronic Clinical Quality Measure (eCQM)
          1.8 Level Of Analysis
          1.20 Testing Data Sources
        • 1.14 Numerator

          The number of individuals from the denominator with concurrent use of opioids and benzodiazepines for >=30 cumulative days during the measurement year.

        • 1.15 Denominator

          The denominator includes individuals >=18 years of age with >=2 prescription claims for opioid medications on different dates of service and with >=15 cumulative days’ supply during the measurement year. Individuals with cancer, sickle cell disease, or in hospice are excluded.

        • Exclusions

          Individuals with cancer, sickle cell disease, or in hospice at any point during the measurement year are excluded from the denominator.

        • 1.13a Data dictionary not attached
          No
        • Most Recent Endorsement Activity
          Endorsed Patient Safety Spring Cycle 2021
          Initial Endorsement
          Last Updated
        • Steward
          Pharmacy Quality Alliance
          Steward Organization POC Email
          Steward Organization Copyright

          COPYRIGHT 2021 PQA, INC. ALL RIGHTS RESERVED

              • Risk adjustment approach
                Off
                Risk adjustment approach
                Off
                Conceptual model for risk adjustment
                Off
                Conceptual model for risk adjustment
                Off